A virus can be used to kill triple-negative breast cancer cells and tumours grown from these cells in mice, finds a new research.
Understanding how the virus kills cancer cells may lead to new treatments for breast cancer, according to Penn State College of Medicine researchers.
Adeno-associated virus type 2 (AAV2) infects humans, but is not known to cause sickness.
“Treatment of breast cancer remains difficult because there are multiple signalling pathways that promote tumour growth and develop resistance to treatment,” said Craig Meyers, professor of microbiology and immunology at Pennsylvania State University in the US.
In prior studies, the researchers tested the virus on a variety of breast cancers that represent degrees of aggressiveness on human papillomavirus-positive cervical cancer cells.
- Home Minister Rajnath Singh Assures Safety Of All Tourists Stranded On Havelock Island
- Government To Waive Service Tax On Debit, Credit Card Transactions Of Up To Rs 2,000
- President Pranab Mukherjee Criticises Parliament Disruptions Over Demonetisation
- Pakistan International Airlines Flight Carrying Over 40 Passenger On Board Crashes
- Shah Rukh Khan On Raees Clash With Kaabil: It’s Impossible To Have A Solo Release In India
- US-President Elect Donald Trump Named TIME’s Person Of The Year 2016
- O. Panneerselvam: 10 Things You Need To Know
- PM Narendra Modi Slams Opposition For Not Letting Parliament Function
- Nawazuddin Siddiqui On Working In Raees: Was Nervous To Shoot With Shah Rukh Khan
- Bathinda Dancer Murder: Video Showing Accused Opening Fire At Marriage
- 5 Lesser Known Facts About Sasikala Natarajan
- Congress Leader Shashi Tharoor’s Delhi Home Burgled: Here’s What Happened
- Reserve Bank Of India Keeps Repo Rate Unchanged Post Demonetisation
- Bigg Boss 10 Dec 06 Review: Swami Om Pees In Kitchen
- Lenovo k6 Power Video Review
The virus initiated apoptosis – natural cell death – in cancer cells without affecting healthy cells.
Treatment of breast cancer differs from patient to patient due to differences in tumours.
A triple-negative breast cancer is typically aggressive.
“There is an urgent and ongoing need for the development of novel therapies which efficiently target triple-negative breast cancers,” Meyers said.
In the current study, the researchers tested AAV2 on a cell-line representative of triple-negative breast cancer.
The AAV2 killed 100 percent of the cells in the laboratory by activating proteins called caspases, which are essential for the cell’s natural death.
AAV2 mediated cell killing of multiple breast cancer cell lines representing both low and high grades of cancer and targeted the cancer cells independent of hormone or growth factor classification.
“These results are significant, since tumour death in response to therapy is also used as the measure of an effective chemotherapeutic,” Meyers said.
The findings appeared in the journal Cancer Biology & Therapy.